Alliancaude e Participacoes (BSP:AALR3) Research & Development: R$0 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:AALR3 Allianca Saude e Participacoes SA BSP:AALR3
49 GF Score
Price R$3.20
GF Value R$9.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Alliancaude e Participacoes Research & Development?

Alliancaude e Participacoes BSP:AALR3 -1.54% 49 Research & Development is R$0 Mil as of Sep. 2025. GuruFocus rates BSP:AALR3 with a GF Score™ of 49/100 and a GF Value™ of R$9.40 (Possible Value Trap). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Alliancaude e Participacoes's Research & Development for the three months ended in Sep. 2025 was R$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 was R$0 Mil.

Alliancaude e Participacoes  (BSP:AALR3) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alliancaude e Participacoes Research & Development Related Terms

Alliancaude e Participacoes Research & Development Historical Data

* Premium members only.

The historical data trend for Alliancaude e Participacoes's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alliancaude e Participacoes Research & Development Chart

Alliancaude e Participacoes Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Alliancaude e Participacoes Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSP:AALR3
49GF Score
Allianca Saude e Participacoes SA BSP:AALR3
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alliancaude e Participacoes Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of R$0 Mil mean?
Alliancaude e Participacoes (BSP:AALR3) has a Research & Development of R$0 Mil as of Sep. 2025. Research and development expense is the total cost for research and development activities. View historical data on Alliancaude e Participacoes and its competitors.
Is Alliancaude e Participacoes' Research & Development too high?
Alliancaude e Participacoes' current Research & Development is R$0 Mil. Overall, Alliancaude e Participacoes has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alliancaude e Participacoes' Research & Development compare to TMO and DHR?
Alliancaude e Participacoes' Research & Development of R$0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Alliancaude e Participacoes and its competitors. Alliancaude e Participacoes's current Research & Development is R$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alliancaude e Participacoes stock overvalued right now?
Based on GuruFocus' analysis, Alliancaude e Participacoes (BSP:AALR3) is currently considered Possible Value Trap. The stock's GF Value™ is R$9.40, compared to a current price of R$3.20 — trading 66% below its estimated fair value. The current Research & Development is R$0 Mil. Alliancaude e Participacoes' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Alliancaude e Participacoes (BSP:AALR3), the current Research & Development is R$0 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alliancaude e Participacoes (BSP:AALR3) Overvalued in 2026?

Based on GuruFocus' analysis, Alliancaude e Participacoes stock appears to be undervalued. The current stock price of R$3.20 is trading 66% below its estimated GF Value™ of R$9.40. GuruFocus considers Alliancaude e Participacoes to be Possible Value Trap.

Key valuation signals for BSP:AALR3:

  • Research & Development: R$0 Mil
  • GF Value™: R$9.40 vs. price of R$3.20 (66% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the BSP:AALR3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alliancaude e Participacoes Business Description

Address Rua Marselhesa, no. 500, 7th floor, Andar Vila Mariana, Sao Paulo, SP, BRA, 04020-060
Allianca Saude e Participacoes SA formerly Centro de Imagem Diagnosticos SA - Alliar is a diagnostic imaging company consisting of MRI machines, CT scanners and ultrasound machines. Its products include diagnostic medicine, diagnostic imaging and clinical analysis. The company is also engaged in the import of medical and hospital equipment, diagnosis kits, and related goods; Providing health consulting, advisory, courses and lectures.
49GF Score

Get the complete analysis for BSP:AALR3

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$3.20
Price
R$9.40
GF Value